Literature DB >> 6976494

[Sphincter-preserving operations in cases of ulcerative colitis (author's transl)].

J Funovics, E Kovats, R Rauhs.   

Abstract

Eighteen cases of operated ulcerative colitis are described. In 15 cases ileorectal anastomosis was performed. In one case, the rectum had to be excised because of a massive rectal haemorrhage; in another case, the anastomosis had to be separated Hartmann's operation) because of a dehiscence of the anastomosis. A re-examination of 13 patients shows full continence in 12 cases; one patient was incontinent with regard to flatus. The Karnofsky Index shows 100 in 10 patients, and 90 in 3 patients. The sigmoidoscopy reveals normal rectal mucosa in 6 patients, a moderate colitis in 5 patients and a severe colitis in 2 patients. There are only two indications for rectal excision in our opinion: uncontrollable rectal haemorrhage and carcinoma (dysplasia).

Entities:  

Mesh:

Year:  1982        PMID: 6976494     DOI: 10.1007/BF01270603

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  5 in total

1.  The development of carcinoma of the large intestine in ulcerative colitis.

Authors:  I M DAWSON; J PRYSE-DAVIES
Journal:  Br J Surg       Date:  1959-09       Impact factor: 6.939

2.  Primary resection of the colon in ulcerative colitis.

Authors:  G G MILLER; C M GARDNER; C B RIPSTEIN
Journal:  Can Med Assoc J       Date:  1949-06       Impact factor: 8.262

3.  Resection of the rectal mucosa, colectomy, and anal ileostomy with normal continence.

Authors:  J DEVINE; R WEBB
Journal:  Surg Gynecol Obstet       Date:  1951-04

4.  Three hundred cases of diffuse ulcerative colitis treated by total colectomy and ileo-rectal anastomosis.

Authors:  S O Aylett
Journal:  Br Med J       Date:  1966-04-23

5.  The risk of cancer following colectomy and ileorectal anastomosis for extensive mucosal ulcerative colitis.

Authors:  S F Grundfest; V Fazio; R A Weiss; D Jagelman; I Lavery; F L Weakley; R B Turnbull
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.